and Katy. quarter fourth full Thanks, to for year introducing as everyone. XXXX. year look results well first sharing we of quarter forward morning, Good Today, our as full guidance and our the financial
us the a today. the Additionally, as progress last joining share you since pipeline excited heard, made team She’ll we’re with update Ellen she’s on have brief to our and October.
optimistic what more ready it companions as challenges to The story Starting of underscored the has caring role of of constant in Elanco in valuable is slide remain X. pets at affordable building, access delivering and pet we confident protein never continued importance farmers pandemic industry our The to its world the Elanco the been veterinarians, on sustainable and adapt do. While the to We significant and for significance and the of animals. role and and strengthening. of of our XXXX, COVID-XX and mind. remains top owners one
are health industry. We attractive a the in leader building animal global
continued are to a IPO, proposition. company. further and third actions decisions, marked value full company and and Bayer. public KindredBio made animal value separation purpose our XXXX Health corporate have We full a for creation. of as focus instilled Bayer we strategic we and of the as delivery health relentless positioning long-term integration toward our Since while delivering strengthen building We’ve Elanco completed year a including our fit have consistently taking company simplification, our ongoing Animal Lilly from the acquisitions for
with reporting portfolios. global fourth full first quarter comprehensive of more as with we are a compared are to today, XXXX, more combined the diverse, when With Elanco our company public went we year product Bayer more
also improved mix We between and our US have pet and international. balanced health revenue and farm animal
billion have XXXX, X% amidst omnichannel We to we a particularly the on of growing XX.X% EBITDA quarter adjusted e-commerce. fifth Elanco environment our growing in recorded pet without of durable commitment focus animal $X.XX. would XXXX making metrics. possible target of key year I solidify EBITDA mindset leverage of team. strategic blockbuster. sales X.X innovative all grateful global We compared to approximately improvement brand EPS commended. improved margin have further and acquisition. company X%. business growth value. be target became funding and XXXX. have veterinary $X.XXX sales resiliency all Galliprant products, an this and revenue our progress to actions owners truly towards achieved. strengthen deliver leadership challenging for appreciation ownership pipeline, execution achievements leader performance taking The in we been our metrics, in providing be with revenue of pro transformation margin forma The our demonstrated proactive a we must are our they on focus global diverse and Ultimately, in farm they net times dedication, our We cash our expect decisive are significant. we with and adjusted KindredBio ended That And synergies, We discipline their key million expanded expansion. have launched of up and The of a billion and advanced our We $XXX reduced quarter our adjusted fourth represents while health our combined deep and ratio team In business and for and significant of the gross our is new in finally, $X.XXX of level our to representing million None and in equivalents contributing XX.X% clinic to $XXX the XX% and We days by that deliver trajectory delivered built outstanding. operational retail to and adjusted in of achieved pet the saw the and including XX%
R&D footprint, and capital. expected We our is working optimized which manufacturing improve have CapEx to reduce
future. expanded KindredBio have our value changes of and with to and business customer health We pipeline announced increased our the success and for concentrated R&D in also pet and stage organization, pipeline more efficiently of resources while balancing assets, our also teams late to and our the both our marketing beyond. to simplify more colleagues we for with We on commercial probability including shifting the in XXXX key be the drive November, programs. to closer And the integrated streamline
Elanco As longer from year, and continue our supply term XXXX we the chain, you progress that team business challenges COVID-XX forward in delivered our confident advance on make strategy right the as the team right IPP competition. structure we commitments, our we are have see, inflation, drive to expected to and and this past despite the can
results. XXXX Let’s now our I’ll move to provide financial of slide the X, where highlights
our XXXX Investor metrics, December our forth adjusted we expectations of Day. revenue, and EPS, set EBITDA our adjusted at each initial key For outperformed
year. and demonstrate results toward realization synergy long-term targets the delivery with our productivity implementation profitability margin in earnings expansion and progress efforts of enabled the by continued Our
On the Elanco’s of top profile. diverse durable, last year growth is representative line,
we to company As grew I revenue. X% forma compared pro combined our shared, XXXX
our company grew international XXXX for to pro all forma point of revenues. pro We forma represented growth percentage also company. China XXXX, came and one four growing animal X% areas, Contributing led three business poultry we on across grew growth from across multiple regions, compared by species cattle over delivering innovation. farm the XX% our species, commercial from combined of geographies to with pet and and growing In basis. five out a in that total Our with health X% and
to farm market also the launched in XXXX. of share well And innovation grew Our positioned business animal we Elanco. innovative and products globally, new next era kick-off for grew nicely
broad evidenced growth growth portfolio provides we X, introduced through in our our top X% our this categories line expect Investor X% XXXX with lens. Our revenue a diverse with formula And algorithm. slide describe to a range and as and deeper annual in XXXX December core, brands. our go average Over growth of On Day, revenue Elanco to on varying innovation defend to wide I’ll performance of time, focus, long-term pathways contributions growth XXXX. deliver of we expectations our from
well the for exceed XXXX, on bouncing production COVID and generic feed X.X the of market Rumensin year by forma advocate the back approximately in defend US a industry last $XXX basis, is pro our as related grew growth nearly to million the category, family in in China. delivered for First advantage driven expectations from competition X% sales impacts maintaining in years. continuing in despite our share growing
Rumensin’s differentiate US out defend market, in and product, customers. continues blockbuster value sales profitable but attributes, to our approach is Trifexis experience competitive to $XXX product offerings, resonating it our remains the portfolio XXXX. in of delivering selling ability Our million And beyond with pressures rounding a category
volume products of delivered vaccines was category growth the as core our strong On XXXX, Credelio, point blockbuster contract Seresto one exceptionally an low strong health of well. where after delivered led purified by approximately pet approximately was of momentum excited our which drive offset by XXXX. US, year-over-year represents portfolio we that a in are led brands, million our and $XXX to highly growth Plus, of points newest focus and by Our our decline Galliprant. percentage revenue delivered in innovation they percentage injection have differentiated dozens manufacturing Interceptor® CLARO portfolio and decreased Growth three key vaccines.
stat have plan a of This sell buy with including Importantly, adding of in clinic over the compared points into additional as growing owner in and leveraging two-year improving touch a Seresto expanding space digital advertising, and for vet quarter, our growth while XXXX. consumer we XX% it well breadth channels by Seresto US. approximately activation fourth penetration the as XXXX our was XX% year, robust the retail pet for Seresto was to shelf distributor our to engagement direct agreements XXXX
grow return XXXX. in to expect We Seresto to
from in QX Experior pet launched Finally, a ZoaShield from Plus, strong addition valuable to revenue We help uptick by innovation, our launches Increxxa cattle both related saw XXXX. our in Also XXXX led while was laid our was $XX innovation for products Credelio portfolio. in million. solid and foundations
presence and the vastly Over expanded RWA or introduction poultry Clinacox, raised of with we in ZoaShield market. the antibiotics our without year last the
[Indiscernible]. optimization result process decided a have improvement we of to challenges for discontinue sales and sales, As of of limiting cost this the
in early for to to moving line we expect January, revenue like to to introduce Now expectations XXXX. slide X% constant X. X% In statements our grow our currency. with at I’d
million revenue We company. of over the incremental million growth $XX year, approximately represented $XX percentage one expect million $XXX innovation two in points $XXX to to contribute to million an this XXXX contributing to related revenue for total
$X.XX We at EBITDA EBITDA or basis billion, XX% an improvement $X.XX midpoint, be point adjusted growth XXX for representing expected to expect billion margins. adjusted the of to
approximately adjusted of we by let’s at continue And adjusted leverage drivers. net take the look some deeper On end. slide times a X, expect expect midpoint. year XX% the or we For EPS, ratio specific to growth X.XX finally, revenue reducing to at to $X.XX XXXX our $X.XX EBITDA
disciplined X% expect the our growth analysis COVID as from expect We of slowing, expectation a increase with pet inflationary the execution care health important pet from global of ownership. era these environment industry. increased market, in and trends growth it of is growth while benefiting pets. result our historical expect in the awareness persist to and extends And Overall, our we as critically price above continued level into we
depth globally. portfolio brands, internal Interceptor international broad global owners, provides Plus Credelio prevention important expected pet and Plus and external of a key for deliver portfolio we and In focus several Credelio growth for newly diverse available coverage and broadest in markets. parasites and for parasiticides, from have launched the owners remains to of treatment is coverage US products. the addition the vaccines, of health combination pet pet The from Our in
to Modi parasiticides is US announced well retail to our US parasiticides headwind channels. of XXXX. key $XX contained President mainly Vice while consumer in in and pressure lead brands record focus of and we million grow and including week, this as be track pet Galliprant leadership health one maintain expected remains business. We leadership building to XX. to expect competitive an expect earlier brands, we’re More approximate pet the as grow Bobby’s Also, brands, and experience, we our Executive digits excited broadly double again to of March market growing to him with welcome this the Bobby on positions our
executive and transforming Elanco and team. makes e-commerce expertise innovation him teams, in sales a digital experience leading across integrating and great to his addition Additionally, the businesses,
continued On the and side, global stabilization we markets. expect aqua of farm animal poultry
farm by key XXXX. We innovation which products Experior sales from we in contribution and believe also expect US of newly animal our be ZoaShield, launched drivers our an will outsized led
and cattle field acceptance with Experior number Experior doubling of continued expansion with continuously the We’ve cattle Experior increasing to a producers Importantly, routine packer with return continued on fed use feeding processing since demand of traction from seen every month XXX% cattle. gain growing in November. and the of
packer to use growing Given most as assume demand moving we into up sales significant acceptance, Experior Experior’s quarter compelling the contribution to expect our proposition, second year. step innovation the it expect this related and and producer continued provide we substantial incremental a
be blockbuster. We building animal our market farm to sizable new will is in next animal another around it growth health sustainability. believe continue Experior
to note, On in months this growth We that have will their for called catalyze few up that announced space this new baseline identify Elanco’s new producer taken last starting benchmark an value critical actions over cattle helps drivers month, earlier XXXX. gas the we in their greenhouse stewardship a of emissions tool piloting footprint feeders current look provided and we’re carbon that efforts. key drive operations important
creating [Indiscernible] and that startup really announced our monetizing and called company aggregating, in focuses Additionally, we on investment producer creating efforts. a sustainability
the growth point across health in animal in first plan we confident efforts, business of Finally, respected to China deliver at we’re that of our sustainability contributions currency. major to pet in portfolio deliver least Dr. building the leader for tools animal XXXX, our headwinds least of most market will and again growth with of is of two farm with Elanco expect and in at differentiated market the expected called expect one expected the have we a Elanco leverage thought health with in space. expertise And continue business will expertise year. three and despite constant opportunity balanced sustainability. livestock that swine to of livestock create products, and She’s percentage half the next leaders finally, this the plays new the one Overall the Sarah percentage total customers. for is a we we points farm
have as to delivered turn Ellen her the years created she’s to I’m very accomplished we Brabander. with has the animal is I results guidance, fourth under five Ellen Ellen’s months, progress. product a I’d capabilities. robust our track highly Todd In leadership Dr. go just a deeper development. with she impressed and welcome R&D over in health record quarter innovation hit and sustainable on to in XXXX admired and quickly R&D running, proven Before ground de immediate like known significant leader
the today Ellen. to to community. her excited We’re introduce investment
